Collegium Pharmaceutical Inc
NASDAQ:COLL

  • LAST PRICE
    30.5000
  • TODAY'S CHANGE (%)
    -0.2100 (-0.6838%)
  • Bid / Lots
    30.0000/ 1
  • Ask / Lots
    31.0000/ 1
  • Open / Previous Close
    30.7700 / 30.7100
  • Day Range
    30.4300
    31.1100
  • 52 Week Range
    25.1600
    42.2873
  • Volume
    198,795

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 12, 2024

  • Nov 7, 2024

      Show headlines and story abstract

    • 5:25PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: COLL

      By Sabela Ojea

      Collegium Pharmaceutical said it named Vikram Karnani as chief executive, effective Nov. 12.

      The specialty pharmaceutical company on Thursday said that Karnani, who will also be joining the board, replaces interim CEO Michael Heffernan.

    • 4:14PM ET on Thursday Nov 07, 2024 by MT Newswires
      Companies Mentioned: COLL
      04:14 PM EST, 11/07/2024 (MT Newswires) -- ...

    • 4:02PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: COLL
      for the nine months ended September 30, 2024 and 2023 were 26.0% and 22.8%, respectively. (2) Adjusted weighted-average shares - diluted were calculated using the "if-converted" method for our convertible notes in accordance with ASC 260, Earnings per Share. As such, adjusted weighted-average shares -- diluted includes shares related to the assumed conversion of our convertible notes and the associated cash interest expense added-back to non-GAAP adjusted net income. For the three months ended September 30, 2024 and 2023, adjusted weighted-average shares -- diluted includes 6,606,305 and 7,509,104 shares, respectively, attributable to our convertible notes. For the nine months ended September 30, 2024 and 2023, adjusted weighted-average shares -- diluted includes 6,606,305 and 6,530,392 shares, respectively, attributable to our convertible notes. In addition, adjusted earnings per share includes other potentially dilutive securities to the extent that they are not antidilutive.

    • 4:02PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: COLL
      for the nine months ended September 30, 2024 and 2023 were 26.0% and 22.8%, respectively. (2) Adjusted weighted-average shares - diluted were calculated using the "if-converted" method for our convertible notes in accordance with ASC 260, Earnings per Share. As such, adjusted weighted-average shares -- diluted includes shares related to the assumed conversion of our convertible notes and the associated cash interest expense added-back to non-GAAP adjusted net income. For the three months ended September 30, 2024 and 2023, adjusted weighted-average shares -- diluted includes 6,606,305 and 7,509,104 shares, respectively, attributable to our convertible notes. For the nine months ended September 30, 2024 and 2023, adjusted weighted-average shares -- diluted includes 6,606,305 and 6,530,392 shares, respectively, attributable to our convertible notes. In addition, adjusted earnings per share includes other potentially dilutive securities to the extent that they are not antidilutive.

Peers Headlines